Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Advantage, Incorporated

Neither a doctor nor a teaching hospital

Research payments

$3,355,797

78 payments

Through program year 2025, Clinical Research Advantage, Incorporated is reported as receiving $3,355,797 in research payments, across 78 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $836,498 8
2024 Research $493,427 14
2023 Research $3,363 5
2022 Research $26,538 3
2021 Research $133,111 14
2020 Research $1,207,345 16
2019 Research $655,516 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $3,355,797 78 payments
Studies the money was for Research payments · program years 2019–2025
  1. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $1,082,984 19 payments
  2. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $642,762 6 payments
  3. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $399,642 6 payments
  4. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $319,842 5 payments
  5. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $239,860 3 payments
  6. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $124,376 7 payments
  7. A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $114,526 2 payments
  8. Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) $100,559 2 payments
  9. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod $86,758 5 payments
  10. Phase III Long Term Roll Over Psoriasis $77,935 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record